Navigation Links
The potent anti-leukemia activity of Berbamine

Chronic myeloid leukemia (CML) is a pluripotent hematopoietic stem cell disorder characterized by accumulation of mature and immature granulocytes in peripheral blood and bone marrow due to uncontrolled growth // and resistance to apoptosis. The dysregulated activity of the bcr/abl oncoprotein tyrosine kinase, which is encoded by the bcr?abl fusion gene, has been shown to be responsible for the malignant phenotypes.

Gleevec, which is an inhibitor of the bcr/abl tyrosine kinase, has been a remarkable success for the treatment of CML. However, a significant proportion of patients chronically treated with Gleevec develop resistance. Thus, new approaches that override the resistance are crucial to the development of curative therapies for CML.

A recent study, to be published in Leukemia Research (available online 14 July 2005) describes the anti-leukemia activity of a natural small molecular compound, berbamine from plant Berberis amurensis that can selectively induce cell death of both Gleevec-sensitive and -resistant Ph+ CML cells.

Importantly, the results in this study show that berbamine is also active against Gleevec-resistant leukemia cells. It is of interest to note that berbamine down-regulates p210 bcr/abl oncoprotein of Ph+ leukemia cells, suggesting that this compound have different anti-leukemia mechanism from that of Gleevec.

The results indicate that up to 76% of leukemia cells were apoptotic cells after treatment with berbamine at concentration of 16 ì g/ml for 48 h, suggesting that the growth inhibition of berbamine for leukemia cells is caused by apoptosis of leukemia cells. Results also suggest that berbamine-induced apoptosis is mediated via caspase-3-dependent pathway.

Another important feature of berbamine is the very desirable safety that is not often seen in conventional chemotherapeutic agents. In addition, berbamine is widely used to improve normal hematopoiesis and immune function of c ancer patients in China.

The authors conclude that berbamine might be a novel bcr/abl inhibitor with potent anti-leukemia activity, and that the potency of berbamine against both Gleevec-sensitive and -resistant Ph+ leukemia cells, and its distinct mechanism of anti-leukemia activity warrant further investigation of berbamine for the treatment of CML

Related medicine news :

1. Hepatitis E virus made impotent
2. Unwed mothers find it difficult to attract potential life partner
3. Unpasteurised juices found to be potential health hazards
4. The many facets of milk and its health potential
5. Artificial sweetener, Aspartame, may be the potential cause of lymphoma, leukaemia
6. Alcohol a potential carcinogen: knocking on the door: pay heed!
7. A potent causative agent of dental flourosis: Fluoride
8. Quebec arming itself to combat a potential influenza pandemic
9. Smoking Is a Vital Cause among Impotent Men
10. Pluripotent ESC, To Serve As an Effective Therapy for Many Diseases
11. Estrogen also a potential neurotransmitter
Post Your Comments:

(Date:11/30/2015)... ... November 30, 2015 , ... Scott ... one of a select few plastic surgeons in the New York City area ... SculpSure™ is the world’s first heat-induced laser treatment for fat loss in the ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... provider of enterprise Time and Attendance/Workforce Management cloud-based solutions, announced today that ... Program with competencies in the Application Development, demonstrating a “best-in-class” ability and ...
(Date:11/30/2015)... MN (PRWEB) , ... November 30, 2015 , ... ... of a new product dealer. Joining more than 30 HealthPostures’ dealers located throughout ... foot space and increase the number of corporate, industrial, manufacturing and government workers ...
(Date:11/30/2015)... ... November 30, 2015 , ... CTI ... services which empower organizations through communication analytics, announced today that their Proteus® VoIP ... manage their service quality. , Proteus® VoIP QMS (Quality Management System) ...
(Date:11/29/2015)... St. Petersburg, FL (PRWEB) , ... November 30, 2015 , ... The Cyber Monday deal ... webstore. , It is the right time to get gifts for the skin care lover ... bow on top filled with serums . This year, the 3 serums are staples: Collagen, ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... IRVINE, Calif. and REHOVOT, Israel ... privately held specialty pharmaceutical company focused on acquiring and ... disorders, today announced the appointment of Keith A. ... directors. Gregory J. Flesher , chief executive ... experience in building successful organizations.  As chairman, he will ...
(Date:11/30/2015)... , November 30, 2015 ... Breast Care has entered into a multi-year agreement ... practice. This will allow Kentucky Breast Care to increase ... exceptional care for their patients. --> ... Breast Care has entered into a multi-year agreement ...
(Date:11/29/2015)... --  Royal Philips  (NYSE: PHG, AEX: PHIA) revealed a ... Radiological Society of North America Annual Meeting (RSNA), beginning ... Chicago . Visitors to the Philips ... of integrated Diagnostic Imaging, Clinical Informatics, Image Guided Therapy ... workflow and create a superior patient experience. ...
Breaking Medicine Technology: